Output Explorer

Every prompt in the paper, and what each model wrote back.

Answer a question about a scanned page from its OCR text. Scored by exact match and ANLS against the accepted answers.

13 of 5,330 prompts

Nearby prompts. All 5,330 DocVQA prompts

PromptDocVQA · pageyrvw0217_55.png

What is the CE/TMG 0.0625(CC) vs Placebo - SEM FOR Cycle 16?

OCR text of the page · 2,087 characters; the scanned image itself is not published
4.9 Body Weight
In year 1 of the study, the CE/TMG groups had significantly less weight gain than the
placebo group at cycles 6 and 9 (p<0.05) for the continuous combined groups and at
3,6 and 9 for the sequential groups (p<0.01).
CHANGES IN BODY WEIGHT
--CE/TMG 0.0625 (CC) vs P
--CE/TMG 0. 125 (SEQ) vs Placebo ---
Adjusted Mear
Adjusted Mean
Cycle
Difference
SEM
p-Values
Difference
SEM
p-Values
-0.01
0.18
0.97
.0.01
0.18
0.094
0.57
0.25
0.020*
0.70
0.24
0.004**
13
-0.76
0.29
0.008*
-0.74
0.28
0.009**
-0.44
0.34
0.19
0.89
0.3
0.008**
16
.0.41
0.52
0.43
-1.04
0.52
0.044*
19
0.02
0.55
0.96
0.61
0.54
0.26
22
26
-0.19
0.56
0.74
.0.76
0.55
0.17
0.14
0.58
0.81
0.97
0.58
0.98
a: Adjusted based on a 1-way analysis of covariance. SEM: Standard error of the
adjusted mean
* p < 0.05, ** p < 0.01
4.10 Quality of Life
The influence CE/TMG on quality of life (Qol) was assessed by identifying changes on
the Women's Health Questionnaire (WHQ) and the Medical Outcomes Study Short
Form-36 (SF-36) questionnaire. The WHQ measures the patient's own assessment of
her changes in health and well-being during the menopause transition. The SF-36 is a
generic measure of functioning and well being not related to any specific age or gender
groups.
The analysis indicated that administration of continuous combined CE /TMG 0.0625 mg
and sequential CE /TMG 0.125 mg to postmenopausal women leads to significant
improvements in Qol when compared with placebo. As measured by the WHQ,
improvements were observed in the domains of vasomotor symptoms, sleep problems,
somatic symptoms, memory/concentration, sexual behavior, and attractiveness; no
significant differences were seen for the domains of anxiety/fears and depressed mood.
For the sequential regimens, as with any sequential regimen designed to provide
regular monthly withdrawal bleeding, scores for the menstrual symptoms domain were
less favorable (p < 0.05) compared with the placebo group.
Confidential
17 of 42
Confidential Pursuant to Confidentiality
KERZC001-000290
Order
Source: https://www.industrydocuments.ucsf.edu/docs/yrvw0217
System prompt · identical for every setup
Answer the question using only the OCR text from a single document page. Return only the answer, with no explanation. Preserve the answer wording from the OCR text when possible.
Expected answer
0.52
Models
4 of 4 columns · click a model to add or remove it

Ours

Exact match

0.52

4 characters5 tokens

Aux 2015

Wrong

The question asks for the CE/TMG 0.0625 (CC) vs Placebo - SEM for Cycle 16.

Looking at the provided text, I see:

  • "4.9 Body Weight"
  • "In year 1 of the study, the CE/TMG groups
179 characters64 tokens

PiT-FT 2015

Wrong

<|<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<

64 characters64 tokens

ChronoGPT 2015

Wrong

-0.0625 (CC) vs Placebo - SEM FOR Cycle 16 -0.125 (SEQ) vs Placebo - SEM FOR Cycle 16 -0.0625 (CC) vs Placebo - SEM FOR Cycle 16 -0.125 (SEQ) vs Placebo - SEM

158 characters64 tokens